flag
International
  • flag
    United States
  • The Challenge
  • The Solution
  • The Evidence
  • News & Events
  • Resource Center

Access videos, images and more to help you and your patients get the most out of the OMNI™ Surgical System.

login

References
1. Market Scope Report, as presented at OIS MIGS Breakfast at AAO 2017.
2. Grant WM. Experimental aqueous perfusion in enucleated human eyes. Arch Ophthalmol 1963; 69:783–801.
3. Rosenquist R, Epstein D, Melamed S, et al. Outflow resistance of enucleated human eyes at two different perfusion pressures and different extents of trabeculotomy. Curr Eye Res 1989; 8:1233–1240.
4. Battista SA, Lu Z, Hofmann S, et al. Reduction of the available area for aqueous humor outflow and increase in meshwork herniations into collector channels following acute IOP elevation in bovine eyes. Invest Ophthalmol Vis Sci 2008; 49:5346–5352.
5. Hirsch L, Cotliar J, Vold SD, Selvadurai D, Campbell A, Ferreiria G, Aminlari AE, Cho AS, Heersink S, Hochman M, Gallardo M, Williamson BK, Phan R, Nelson C, Dickerson Jr. JE. Canaloplasty and Trabeculotomy ab interno with the OMNI System Combined with Cataract Surgery in Open-Angle Glaucoma. Journal of Cataract and Refractive Surgery. DOI (DOI: 10.1097/j.jcrs.0000000000000552)
6. Klabe K. Standalone Trabeculotomy and Viscodilation of Schlemm Canal and Collector Channels in Open-Angle Glaucoma. January 2021 (insert to Cataract & Refractive Surgery Today Europe).

OMNI Surgical System is CE Marked in the European Union

Indications and Safety Information

Read More

4040 Campbell Ave., Suite 100
Menlo Park, CA 94025

Sight Sciences UK, LTD is a limited company registered in England and Wales.
Registered Number: 13094159
Registered Office: 5 New Street Square, London, EC4A 3TW

tel: 877-266-1144

Info@sightsciences.com

  • Privacy Policy
  • Cookie Policy
©2023 Sights Sciences, Inc. 09/22 OM-1493-OUS.v3

Indications and Safety Information

Indications for use

The OMNI™ Surgical System is indicated for the catheterization and transluminal viscodilation of Schlemm’s canal and the cutting of trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma.

Contraindications

1. Do not use the OMNI in any situations where the angle is compromised or has been damaged (e.g., from trauma or surgery), since it may not be possible to visualize the angle or to properly pass the microcatheter.
2. Do not use the OMNI in patients with angle recession; neovascular glaucoma; chronic angle closure; narrow-angle glaucoma; traumatic or malignant glaucoma; or narrow inlet canals with plateau iris.

Warnings

1. Do not use in cases where there is insufficient visibility to properly see the angle. The following conditions may prohibit sufficient visualization of the angle required for safe and successful cannula placement: corneal edema, corneal haze, corneal opacity, or any other conditions that may inhibit gonioscopic view of the angle and intended cannula entry location.
2. Perform gonioscopy prior to taking a patient to surgery to exclude congenital anomalies of the angle, anterior segment dysgeneses, peripheral anterior synechiae (PAS), rubeosis, and any other angle abnormalities that could lead to improper placement of the cannula and microcatheter and pose a hazard.
3. Maintain direct microscopic or gonioscopic visualization of the cannula tip and microcatheter tip at all times during the procedure to facilitate advancement and to avoid inadvertently damaging intraocular structures, kinking the microcatheter or unintended tearing of trabecular meshwork.

Potential adverse events

Adverse events that may be reasonably associated with the use of the OMNI™ System in the eye include but are not limited to the following: anterior chamber shallowing, severe, prolonged, or persistent intraocular inflammation including toxic anterior segment syndrome (TASS), endophthalmitis or other ocular infection, aqueous misdirection, Descemet’s membrane tear or detachment, intracorneal hematoma, choroidal effusion, suprachoroidal hemorrhage, corneal decompensation, corneal injury, corneal edema or opacification, unintended trabeculotomy, cyclodialysis cleft, hyphema, hypopyon, hypotony, hypotony maculopathy, IOL dislocation, cataract formation, iris injury, tear, or iridodialysis, loss of vitreous, perforation of sclera, posterior capsular bag rupture, proliferative vitreoretinopathy, pupillary block, pupillary membrane formation, retinal detachment, retinal dialysis, retinal flap tears, secondary surgical intervention, including but not limited to glaucoma surgery, and vitreous hemorrhage.

Thank you for message

We appreciate your interest in the OMNI Surgical System. A member of our team will review your inquiry and get back to you as soon as possible during business hours.

    Um mehr über das OMNI® System zu erfahren oder eine Demo zu vereinbaren, füllen Sie bitte das folgende Formular aus.
    Sie werden von einem unserer Mitarbeiter kontaktiert.
    Klicken Sie hier, um die Datenschutzrichtlinie anzuzeigen
    Sight Sciences GmbH
    HRB: 109221
    Büro:
    Kranhaus 1, Im Zollhafen 18, 50678 Köln

      To learn more about the OMNI® Surgical System or arrange a demo please complete the form below.
      You will be contacted by a member of our UK surgical training team.
      Click here to view the privacy policy
      Sight Sciences UK, LTD is a limited company registered in England and Wales.
      Registered Number: 13094159
      Registered Office:
      5 New Street Square, London, EC4A 3TW